Where Can I Buy Research Chemicals
MuseChem, branded in the USA, supplies more than 100,000 legal research chemicals for sale, over 20,000 items in stock ready for shipping. Other than providing research chemicals used for drug research and lab reagents, we service custom compound synthesis, providing inhibitors, agonists, APIs (active pharmaceutical ingredients), chemical standards and many other chemicals for research use
where can i buy research chemicals
MuseChem provides custom synthesis service related to compound chemicals, especially peptide synthesis, and analytical service. Our services help you faster drug discovery and better bio-medical research.
We offer a range of over 90,000 chemicals for research and industry, many of which are unique to Apollo Scientific, with new compounds added regularly. Many products are available from R&D quantities right up to bulk.
Specialists in the manufacture and supply of aromatic, heterocyclic and aliphatic compounds, fluorochemicals and life sciences reagents, offering unrivalled service and expertise in the sourcing and manufacture of available and novel products.
Alfa Aesar, which is located about 30 miles north of Boston, is a unit of Johnson Matthey, a British company that makes specialty chemicals. Alfa Aesar makes chemicals used in drug discovery and development, as well as manufacturing. It had about $123 million in revenue in 2014. It has 480 employees.
Bill Sanders, Ph.D., is an assistant professor in the Department of Pediatrics at the University of Southern California and a researcher within the CHOIR program, Saban Research Institute, Childrens Hospital Los Angeles. His research interests include homeless youth, injection drug use, club drug use, polydrug use, gang youth, youth violence, and general involvement in offending. He is currently an ethnographer and analyst on three-city study of the health risk surrounding the injection of ketamine and a principal investigator on a public health study of gang-identified youth in Los Angeles. Both studies are funded by the National Institute on Drug Abuse. His latest book, Drugs, Clubs and Young People: Sociological and Public Health Perspectives, was published in 2006 by Ashgate.
Stephen E. Lankenau, Ph.D., is an assistant professor at the University of Southern California, Keck School of Medicine, Departments of Pediatrics and Preventative Medicine. Trained as a sociologist, he has studied street-involved and other high-risk populations for the past 10 years, including ethnographic projects researching homeless panhandlers, prisoners, sex workers, and injection drug users. Currently, he is principal investigator of a 4-year NIH study researching ketamine injection practices among young IDUs in New York, New Orleans, and Los Angeles.
Jennifer Jackson Bloom received her MPH with a specialization in epidemiology from the University of California, Los Angeles. She works with the Division of Research on Children, Youth and Families at Childrens Hospital Los Angeles. Her research interests include behavioral risk in substance abusing populations, modeling longitudinal change in substance use and the application of geography to drug abuse research.
Dodi Hathazi graduated with a B.S. in psychology, magna cum laude, from Saint Lawrence University in Canton, New York. She works as an ethnographer with the Division of Research on Children, Youth and Families at Childrens Hospital Los Angeles. Her research interests include polydrug use patterns among homeless traveling youth and reproductive health issues including pregnancy rates and outcomes in high-risk youth. Previously, she worked at the RAND Corporation in Santa Monica, California, in the Survey Research Group where she collected data for three behavioral research projects.
Currently, it is legal to sell and buy SARMs that are marketed simply as research chemicals, which commonly occurs online. However, it is illegal to sell and buy those that are packaged in capsules for human consumption and/or labeled as dietary supplements.8 Furthermore, they cannot be marketed to the public as dietary supplements, and claims regarding their benefits cannot be made.8 Here we review the current clinical literature to assess the health benefits versus risks of using SARMs as performance enhancers.
To date, there are no human clinical studies with Andarine. In the fitness community and on various online forums, it is touted as a muscle-boosting supplement that elicits weight loss and promotes muscle building and repair.25 However, it is regarded as being comparatively weaker than other popular SARMs, so it is commonly stacked with other SARMs.25 Using Andarine by itself at 25 mg per day purportedly improves mood and general wellness, whereas increasing the dose to 50 mg per day only modestly boosts strength, lean mass, and fat burning.25 For bulking, it is recommended that Andarine (50 mg) be stacked with Testolone (10 mg) daily for 8 to 12 weeks.25 For strength, it is suggested that Andarine (50 mg) be stacked with Ligandrol (10 mg) daily for 2 to 3 weeks.25 For cutting, it is advised that it (25 mg) be stacked with Cardarine (20 mg, a non-SARM, paroxisome proliferator-activated receptor-delta agonist) daily for 12 weeks.25 For body recomposition (i.e., simultaneously losing fat and gaining muscle), it is recommended that Andarine (50 mg) be stacked with both Ostarine (25 mg) and Cardarine (20 mg) daily for 9 to 12 weeks.25 The primary side effects reported with Andarine are altered vision (i.e., yellow-tinged) and suppression of testosterone.25
(c) improve and expand domestic biomanufacturing production capacity and processes, while also increasing piloting and prototyping efforts in biotechnology and biomanufacturing to accelerate the translation of basic research results into practice;
(h) elevate biological risk management as a cornerstone of the life cycle of biotechnology and biomanufacturing R&D, including by providing for research and investment in applied biosafety and biosecurity innovation;
(k) engage the international community to enhance biotechnology R&D cooperation in a way that is consistent with United States principles and values and that promotes best practices for safe and secure biotechnology and biomanufacturing research, innovation, and product development and use.
(b) Each report specified in subsection (a) of this section shall identify high-priority basic research and technology development needs to achieve the overall objectives described in subsection (a) of this section, as well as opportunities for public-private collaboration. Each of these reports shall also include recommendations for actions to enhance biosafety and biosecurity to reduce risk throughout the biotechnology R&D and biomanufacturing lifecycles.
(iv) the Department of Energy shall support research to accelerate bioenergy and bioproduct science advances, to accelerate biotechnology and bioinformatics tool development, and to reduce the hurdles to commercialization, including through incentivizing the engineering scale-up of promising biotechnologies and the expansion of biomanufacturing capacity.
(c) within 280 days of the date of this order, provide a plan to the Director of OMB, the ADPD, and the Director of OSTP with processes and timelines to implement regulatory reform, including identification of the regulations and guidance documents that can be updated, streamlined, or clarified; and identification of potential new guidance or regulations, where needed;
(ii) use Federal investments in biotechnology and biomanufacturing to incentivize and enhance biosafety and biosecurity practices and best practices throughout the United States and international research enterprises.
(b) Within 180 days of the date of this order, the Secretary of HHS and the Secretary of Homeland Security, in coordination with agencies that fund, conduct, or sponsor life sciences research, shall produce a plan for biosafety and biosecurity for the bioeconomy, including recommendations to:
(c) Within 1 year of the date of this order, agencies that fund, conduct, or sponsor life sciences research shall report to the APNSA, through the Assistant to the President and Homeland Security Advisor, on efforts to achieve the objectives described in subsection (a) of this section.
(vii) develop, and work to promote and implement, biosafety and biosecurity best practices, tools, and resources bilaterally and multilaterally to facilitate appropriate oversight for life sciences, dual-use research of concern, and research involving potentially pandemic and other high-consequence pathogens, and to enhance sound risk management of biotechnology- and biomanufacturing-related R&D globally; and
In medical and scientific research, as outlined by the National Institute on Drug Abuse (NIDA), there are chemicals that can be used for research purposes, to develop new pharmaceutical remedies or investigate the effects of specific molecules.2 However, research chemicals used to get high are a different type of substance altogether.3 These substances are developed in a lab and frequently have mechanisms of action or effects that mimic those of other abused substances such as marijuana, opioids, or cocaine. These drugs are then sold to people with little understanding of their chemical constituents or actual effects for the mere purpose of recreational use. Although the chemicals may have once derived from legitimate chemical research, the term research chemicals is misleading and hides how dangerous these psychoactive substances can be.1
Research chemicals are commonly classified as synthetic drugs for legal and regulatory purposes. Synthetics are a broad grouping of drugs which include MDMA (ecstasy), ketamine, synthetic cathinones (bath salts), and synthetic cannabinoids (Spice and K2). Many agencies refer to these drugs as new psychoactive substances (NPS), as they are all manufactured in laboratory settings, and many of them have legal analogues that were developed specifically to bypass drug enforcement laws.1 Often, the packaging for these products has the warning label: not for human consumption. 041b061a72